Abstract：Objective: Research the clinical efficacy , serological indexes and neutrotransmitter of Venlafaxine in the treatment of depression . Methods: Select 168 depression patients between October 2015 and January 2017 of our hospital , divided them into two groups called control group and research group randomly, the control group was taken fluoxetine , while research group was combined with Venlafaxine , compared the SF-36 score , HAMD score , serological indexes and neutrotransmitter factors of two groups before and after treatment .Results:The SF-36 score of two groups before treatment had no statistical difference(P>0.05),the SF-36 score of research group 4 weeks and 8 weeks after treatment were both much higher than control group , and had statistical difference(P<0.05),the SF-36 score of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The HAMD score of two groups had no statistical difference(P>0.05),the HAMD score of research group 4 weeks and 8 weeks after treatment were both much higher than control group , and had statistical difference(P<0.05),the HAMD score of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The serological indexes of two groups such as TNF-α、IL-1β、IL-6 had no statistical difference(P>0.05),the TNF-α、IL-1β、IL-6 of research group 4 weeks and 8 weeks after treatment were both much lower than control group , and had statistical difference(P<0.05),the TNF-α、IL-1β、IL-6 level of two groups 4 weeks and 8 weeks after treatment all had statistical difference with pre-treatment respectively(P<0.05).The neutrotransmitter indexes such as Glu、NE、Ach、DA、5-HT and GABA of two groups before treatment had no statistical difference(P>0.05),Glu level of research group 4 weeks and 8 weeks after treatment were both much lower than control group , NE、Ach、DA、5-HT and GABA levels of research group of 4 weeks and 8 weeks after treatment were all much higher than control group , and had statistical difference(P<0.05),Glu、NE、Ach、DA、5-HT and GABA levels of two groups of 4 weeks and 8 weeks after treatment had statistical difference with pre-treatment respectively(P<0.05).Conclusion:The function mechanism of Venlafaxine is related to the expression of cytokines and the regulation of neutrotransmitters ,and the effect is accurate , which can significantly improve the quality of life of patients and promote the alleviation of depression symptoms , and is worthy of clinical promotion.
刘涛, 钟艳丽. 抑郁症患者治疗中文拉法辛对生活质量及脑涨落图仪观察的神经递质的影响[J]. 河北医学, 2019, 25(8): 1316-1320.
LIU Tao, et al. Analysis of Quality of Life and Neutrotransmitter Tested by Encephalofluctuograph of Venlafaxine in the Treatment of Depression. HeBei Med, 2019, 25(8): 1316-1320.
[1]Schwartz TL,Santarsieri D.Neutral implications of psychotherapy,pharmacotherapy,and combined treatment in major depressive disorder[J].Mens Sana Monogr,2016,14(1):30~45. [2] Sachs-ericsson N,Hames JL,JOINER TE,et al.Differences between suicide attempters and nonattempters in depressed older patients:depression severity,white-matter lesions,and cognitive functioning[J].Am Geriatr Psychiatry,2014,22(1):75~85. [3] Harrisberger F,Spalek K,Smieskova R,et al.The association of the BDNF Val66Met polymorphism and the hippocampal volumes in healthy humans:a joint meta-analysis of published and new data[J].Neurosci Biobehav Rev,2014,42(5):267~278. [4] Ali A,Yesudas K F,Palayat A M,et al.Depression and menopaused symptoms in perimenopausal women attending primary care[J].J Evi Based Med Health,2017,4(44):2677~2681. [5] 杨和增,单菲,李敏智.围绝经期抑郁症患者文拉法辛治疗前后脑源性神经营养因子的变化[J].实用医学杂志,2018,34(3):457~459. [6] Guuzel O P,Boysan M,Smolensky M H,et al.Comparison of venlafaxin alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder[J].Journal of Clinical Psychiatry,2015,76(5):645. [7] Cheon E J,Lee K H,Park Y W,et al.Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors:a randomized,prospective,open-label study[J].Journal of Clinical Psychopharmacology,2017,37(3):113~115.
2019, Vol. 25 
冀公网安备13080202000677号